News

International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol® and Mexidol® forte 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension

Abstract. Chronic brain ischemia (CBI) is one of the most common neurological disorders in clinical practice. Objective: to evaluate the efficacy and safety of sequential therapy with Mexidol® solution intravenously and Mexidol® FORTE 250 film-coated tablets, 250 mg orally in patients with and without arterial hypertension (AH) in terms of the drug effect on cognitive functioning, as well as the severity of asthenic, anxiety, vegetative and motor disorders, and quality of life in CBI.

Read More